On Tuesday, Canaccord Genuity revised its outlook on TransMedics Group (NASDAQ:TMDX) shares, reducing the price target to $109.00 from the previous $169.00, yet the firm maintained a Buy rating on the stock. The adjustment follows TransMedics' third-quarter revenue report, which disclosed earnings of $108.8 million, a 64% year-over-year increase but fell short of the analyst's $118.6 million projection and the consensus estimate of $115.0 million.
TransMedics' earnings per share (EPS) also did not meet expectations, coming in at $0.12 compared to the anticipated $0.39 and the consensus of $0.29. The company's revenue downturn was attributed to a softer-than-anticipated season in the U.S. transplant market, with quarter-over-quarter volume declines mirroring the overall market trend. Despite this, the company's market share remained stable from the second to the third quarter.
The firm noted that TransMedics reiterated its full-year 2024 guidance, prompting the analyst to adjust their estimates to align more closely with the mid-point of that guidance range. The analyst suggests that TransMedics may no longer be in a position to exceed expectations but rather is likely to meet them and maintain its current course for the upcoming quarters.
Management indicated that trends had shown improvement in October, raising the question of whether this uptick is sufficient. The company's third-quarter margins were also affected by ongoing plane maintenance costs that impacted service margins and a $2 million investment in non-recurring expenses for the development of an aviation maintenance center and expansion of network operation hubs.
Despite the revenue shortfall, Canaccord Genuity believes that TransMedics could recover, citing ongoing clinical trials in lung and heart that could stimulate further market growth. The firm anticipates more details about the company's pipeline and future guidance to be shared at the investor day scheduled for December 10th in New York City. The analyst expects the stock to experience a significant decline the following day but reaffirms the Buy rating with the updated price target.
In other recent news, TransMedics Group reported third-quarter 2024 revenues of $108.8 million, falling short of analyst and consensus estimates. Despite this, the company reiterated its full-year 2024 guidance, projecting revenues in the range of $425-445 million. TransMedics' shares of the U.S. transplant market were reported as 21% for heart, 27% for liver, and 4% for lung in the same quarter.
Financial services firms Needham and Oppenheimer revised their price targets for TransMedics to $109 and $125 respectively, while maintaining positive ratings. Piper Sandler and TD Cowen also confirmed their positive ratings, highlighting the company's continued success in the organ preservation sector.
In addition, TransMedics recently acquired an 18th aircraft from 77 Aviation, LLC for $14.4 million, enhancing its organ transport capacity. The company also revealed its plan to expand into donation after brain death (DBD) transplants in the next year.
A recent study indicated potential benefits of hypothermic oxygenated machine perfusion in heart transplantation, which could reduce the risk of primary graft dysfunction. These are the latest developments in the company's ongoing efforts to improve organ transplant outcomes.
InvestingPro Insights
TransMedics Group's recent performance, as highlighted in the article, can be further contextualized with real-time data from InvestingPro. Despite the revenue shortfall and reduced price target, the company's financials show some promising aspects. InvestingPro data reveals that TransMedics has experienced substantial revenue growth, with a 137.47% increase in the last twelve months as of Q2 2024. This aligns with the company's 64% year-over-year revenue increase mentioned in the article.
Two relevant InvestingPro Tips shed light on the company's potential: "Net income is expected to grow this year" and "Analysts anticipate sales growth in the current year." These tips support Canaccord Genuity's maintained Buy rating, suggesting that despite recent challenges, TransMedics may still have growth potential.
However, investors should note that TransMedics is "Trading at a high earnings multiple," with a P/E Ratio (Adjusted) of 149.75 for the last twelve months as of Q2 2024. This high valuation might explain the stock's sensitivity to earnings misses, as reflected in the anticipated significant stock decline following the revenue shortfall.
For readers interested in a more comprehensive analysis, InvestingPro offers 15 additional tips for TransMedics Group, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.